SLC22A17

Across TCGA pan-cancer cohorts, SLC22A17 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated SLC22A17 data layer compared with 4 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher SLC22A17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC22A17 expression acts as an unfavorable survival marker, although some lineages such as LGG and PAAD show a favorable association.

UVM, ACC, and LGG are the cancer types where SLC22A17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Median	All	0.417	0.760	<.001	79	view →
ACC	OS	Median	All	0.425	0.802	<.001	76	view →
LGG	OS	Median	All	0.876	0.743	<.001	49	view →
PAAD	DFS	Median	All	0.391	0.192	<.001	41	view →
STAD	OS	Quartile	All	0.359	0.627	.003	41	view →
SKCM	OS	Median	All	0.423	0.265	<.001	33	view →
UCEC	DFS	Quartile	All	0.780	0.887	.003	32	view →
ESCA	DFS	Median	All	0.926	0.454	.006	24	view →
BLCA	DFS	Quartile	II,III,IV	0.247	0.479	.011	21	view →
LUAD	OS	Quartile	All	0.760	0.608	.003	19	view →
CESC	DFS	Quartile	II,III,IV	0.282	0.739	.021	16	view →
SCLC	DFS	Tertile	All	0.442	1.000	.013	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

SLC22A17–UVM (DFS)

Open the UVM breakdown →